author-photo

Felipe de Arriba

University of Murcia

118

Papers

4258

Citations

Citation Trend

Filter By

Papers (87) Sort By

Journal Conference Others

Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial.

2021 Blood Cancer Journal
Show All
- Source
- Cite
- Save
Citations (3)
Tumor cells in light-chain amyloidosis and myeloma show different transcriptional rewiring of normal plasma cell development

2021 Blood
Show All
- Source
- Cite
- Save
Citations (2)
Minimal Residual Disease in Multiple Myeloma: Something Old, Something New.

2021 Cancers
Show All
- Source
- Cite
- Save
Citations (0)
Circulating Tumor Cells (CTCs) in Smoldering and Active Multiple Myeloma (MM): Mechanism of Egression, Clinical Significance and Therapeutic Endpoints

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Selinexor in Combination with Daratumumab-Bortezomib and Dexamethasone for the Treatment of Relapse or Refractory Multiple Myeloma: Initial Results of the Phase 2, Open-Label, Multicenter GEM-Selibordara Study

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
OAB-056: A machine learning model based on tumor and immune biomarkers to predict undetectable measurable residual disease (MRD) in transplant-eligible multiple myeloma (MM)

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group.

2020 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (3)
Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis

2019 Leukemia
Show All
- Source
- Cite
- Save
Citations (11)
Management of adverse events (AEs) observed in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma (MM)

2019 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

2019 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (125)